Idexx Laboratories Inc. (NASDAQ:IDXX)’s share price reached a new 52-week high on Monday . The stock traded as high as $111.95 and last traded at $111.90, with a volume of 152,964 shares trading hands. The stock had previously closed at $110.78.

IDXX has been the subject of several research analyst reports. Canaccord Genuity reaffirmed a “buy” rating and set a $85.00 target price (up from $80.00) on shares of Idexx Laboratories in a research note on Tuesday, April 19th. TheStreet raised shares of Idexx Laboratories from a “hold” rating to a “buy” rating in a research note on Friday, April 29th. Zacks Investment Research cut shares of Idexx Laboratories from a “buy” rating to a “hold” rating in a research note on Monday, July 4th. Northcoast Research raised shares of Idexx Laboratories from a “sell” rating to a “neutral” rating in a research note on Wednesday, August 3rd. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $120.00 price objective (up from $92.00) on shares of Idexx Laboratories in a research note on Wednesday, August 3rd. Four analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $100.80.

The stock has a market capitalization of $9.93 billion and a PE ratio of 50.29. The company has a 50-day moving average price of $98.49 and a 200-day moving average price of $85.31.

Idexx Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, August 2nd. The company reported $0.74 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.62 by $0.12. The business earned $467 million during the quarter, compared to analysts’ expectations of $444.83 million. During the same period in the previous year, the business posted $0.60 EPS. The company’s revenue for the quarter was up 12.9% compared to the same quarter last year. Equities analysts predict that Idexx Laboratories Inc. will post $2.36 earnings per share for the current year.

In related news, Chairman Jonathan W. Ayers sold 60,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 4th. The shares were sold at an average price of $107.69, for a total value of $6,461,400.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director William T. End sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, August 5th. The shares were sold at an average price of $108.50, for a total transaction of $542,500.00. Following the completion of the sale, the director now directly owns 53,564 shares in the company, valued at approximately $5,811,694. The disclosure for this sale can be found here.

A number of hedge funds have recently modified their holdings of the stock. US Bancorp DE boosted its stake in shares of Idexx Laboratories by 7.2% in the fourth quarter. US Bancorp DE now owns 39,115 shares of the company’s stock valued at $2,853,000 after buying an additional 2,612 shares during the period. Advisors Asset Management Inc. boosted its stake in shares of Idexx Laboratories by 2.9% in the fourth quarter. Advisors Asset Management Inc. now owns 17,027 shares of the company’s stock valued at $1,242,000 after buying an additional 487 shares during the period. Principal Financial Group Inc. boosted its stake in shares of Idexx Laboratories by 1.8% in the fourth quarter. Principal Financial Group Inc. now owns 296,034 shares of the company’s stock valued at $21,587,000 after buying an additional 5,318 shares during the period. Finally, Morgan Stanley boosted its stake in shares of Idexx Laboratories by 41.3% in the fourth quarter. Morgan Stanley now owns 272,672 shares of the company’s stock valued at $19,883,000 after buying an additional 79,704 shares during the period.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.